Table of Contents
What Is Clinical Trial Approval in Nepal?
Clinical trial approval Nepal is the mandatory regulatory and ethical authorization process required before conducting any human subjects research involving pharmaceutical products, medical devices, or therapeutic interventions within Nepal. This dual-track system involves both the Nepal Health Research Council (NHRC) for ethical oversight and the Department of Drug Administration (DDA) for regulatory licensing .
Under the Drug Act 2035 (1978) and National Ethical Guidelines for Health Research in Nepal, no clinical trial may commence without obtaining both ethical clearance from NHRC's Ethical Review Board (ERB) and a clinical trial license from DDA . The process ensures participant safety, scientific integrity, and compliance with international Good Clinical Practice (GCP) standards .
Therefore, understanding clinical trial approval Nepal is essential for pharmaceutical companies, research institutions, principal investigators, and sponsors seeking to conduct human trials in Nepal.
Legal Framework for Clinical Trial Approval Nepal
The clinical trial approval Nepal system operates under a multi-layered regulatory structure:
| Law/Regulation | Year | Authority | Key Provisions |
|---|---|---|---|
| Drug Act 2035 (1978) | 1978 | DDA | Section 31: Clinical trial licensing requirement; Section 34: Penalties for unauthorized trials |
| Drug Registration Rule 2038 | 1981 | DDA | Rule 8: Clinical trial application and licensing procedures |
| NHRC Act 1991 | 1991 | NHRC | Mandates NHRC as apex body for health research regulation |
| National Ethical Guidelines for Health Research | 2001 (updated) | NHRC | Comprehensive ethical standards for all health research |
| National Guidelines on Clinical Trials | Current | NHRC | Protocol requirements, GCP compliance, participant protection |
| WHO-ICMR MoU | 2021 | NHRC/ICMR | Collaborative research and regulatory harmonization |
Critical Gap: Despite these laws, Nepal's clinical trial regulatory framework has historically been incomplete, lacking specific guidelines, standard operating procedures (SOPs), and adequately trained personnel . Recent reforms supported by Management Sciences for Health (MTaPS) have begun addressing these deficiencies.
Dual Approval System: NHRC and DDA
Clinical trial approval Nepal requires two separate approvals that operate in sequence:
| Authority | Approval Type | Scope | Timeline |
|---|---|---|---|
| NHRC | Ethical Clearance | Scientific validity, participant protection, informed consent, risk-benefit analysis | 4–8 weeks |
| DDA | Clinical Trial License | Regulatory compliance, drug safety, manufacturing quality, protocol adherence | 2–4 weeks (after NHRC approval) |
Important: DDA typically requires NHRC ethical clearance as a prerequisite before accepting clinical trial license applications .
Step-by-Step Clinical Trial Approval Nepal Process
Step 1: Protocol Development and Internal Review
Before seeking clinical trial approval Nepal, the research team must:
- Develop comprehensive clinical trial protocol following ICH-GCP guidelines
- Conduct literature review and establish scientific rationale
- Define primary and secondary endpoints
- Calculate sample size and statistical power
- Prepare informed consent documents in Nepali and English
- Establish data management and monitoring plans
Step 2: Institutional Review Committee (IRC) Submission
For researchers affiliated with institutions having IRCs:
| Action | Details |
|---|---|
| Submit to IRC | Initial ethical review at institutional level |
| IRC review | Scientific and ethical assessment of protocol |
| IRC approval | Required before NHRC submission |
| Timeline | 2–4 weeks depending on IRC workload |
Nepal currently has 52 functional IRCs across medical institutions and universities .
Step 3: NHRC Ethical Review Board (ERB) Submission
Submit to NHRC's central Ethical Review Board for national-level ethical clearance:
| Required Documents | Purpose |
|---|---|
| Clinical trial protocol (proposal) | Study design and methodology |
| Informed consent forms | Participant rights and voluntary participation |
| Investigator's CV and qualifications | Competency verification |
| Clinical trial agreement letter | Sponsor-investigator contractual terms |
| Budget and funding details | Financial transparency |
| Risk/benefit assessment | Participant safety evaluation |
| Insurance for participants | Compensation for trial-related harm |
| Data safety monitoring plan | Adverse event management |
Step 4: NHRC Ethics Review Process
The ERB follows a structured review procedure :
| Stage | Activity | Timeline |
|---|---|---|
| Technical screening | Completeness check and internal reviewer assignment | 1–2 weeks |
| External expert review | Subject specialists assess scientific and technical content | 2–3 weeks |
| Researcher response | PI addresses reviewer comments | Variable |
| ERB meeting review | Full board discussion and decision | 1–2 weeks |
| Decision communication | Written approval, conditional approval, or rejection | Within 2 weeks of meeting |
| Total NHRC timeline | 4–8 weeks | From submission to decision |
ERB Decision Types:
- Full approval: Study may commence
- Conditional approval: Minor modifications required; resubmission not needed
- Disapproval: Major deficiencies; requires substantial revision and resubmission
Step 5: DDA Clinical Trial License Application
After obtaining NHRC ethical clearance, apply to DDA for the clinical trial license:
| Document | Format | Purpose |
|---|---|---|
| Schedule-12 application form | Prescribed by DDA | Official request |
| NHRC/ERB approval letter | Original | Ethical clearance proof |
| Clinical trial protocol | Final approved version | Study methodology |
| Independent references | Published literature | Supporting objectives and hypothesis |
| Toxicological report | Laboratory data | Drug safety evidence |
| Quality control methods | Analytical data | Manufacturing standards |
| Investigator details | Name, address, qualifications | Competency verification |
| Trial site information | Hospital/institution name and address | Location confirmation |
Step 6: DDA Regulatory Review and Licensing
| Stage | Activity | Timeline |
|---|---|---|
| Application receipt | Preliminary completeness check | 1–2 weeks |
| Technical evaluation | Drug quality, safety, and efficacy assessment | 2–4 weeks |
| Site inspection (if required) | GCP compliance and facility verification | Variable |
| License issuance | Schedule-13 license granted | Upon approval |
| Total DDA timeline | 2–4 weeks | After NHRC clearance |
Step 7: Clinical Trial Registration
Before commencing recruitment, register the trial with:
| Registry | Purpose | Requirement |
|---|---|---|
| Nepal Clinical Trials Registry (NCTR) | National trial database | Mandatory for all NHRC-approved trials |
| WHO International Clinical Trials Registry Platform (ICTRP) | Global visibility | Recommended for international trials |
Step 8: Trial Commencement and Ongoing Compliance
Once clinical trial approval Nepal is complete:
- Obtain final site-specific approvals from participating hospitals
- Begin participant recruitment per approved protocol
- Submit progress reports to NHRC every 6 months
- Report serious adverse events (SAEs) within 24 hours to both NHRC and DDA
- Allow NHRC monitoring and DDA inspections
- Maintain source documents and case report forms per GCP
Ethical Requirements for Clinical Trial Approval Nepal
Core Ethical Principles
The National Ethical Guidelines for Health Research in Nepal mandate adherence to :
| Principle | Application |
|---|---|
| Autonomy | Voluntary informed consent; right to withdraw anytime |
| Beneficence | Research must benefit participants or society |
| Non-maleficence | Minimize harm; risk must not exceed potential benefit |
| Justice | Fair distribution of research burdens and benefits |
| Scientific validity | Methodologically sound; capable of answering research question |
Special Protections for Vulnerable Populations
| Population | Protection Requirements |
|---|---|
| Pregnant women | Research only if potential benefit to maternal/fetal welfare |
| Children | Parental consent + child assent; benefit to child's welfare required |
| Elderly | Enhanced capacity assessment; protection from exploitation |
| Disabled persons | Appropriate consent mechanisms; guardian involvement |
| Prisoners | Strict limitations; coercion prevention |
| Mentally disabled | Legal guardian consent; minimal risk threshold |
| Disaster-affected populations | Special vulnerability recognition; enhanced protections |
Informed Consent Requirements
| Element | Requirement |
|---|---|
| Language | Nepali and English; local dialect if needed |
| Comprehension level | Appropriate to participant's education |
| Voluntariness | No coercion, undue influence, or incentives |
| Right to withdraw | Explicitly stated; no penalty for withdrawal |
| Compensation | Clear terms for trial-related injury or death |
| Confidentiality | Data protection measures explained |
Biological Sample Transfer Restrictions
Critical restriction: Transfer of raw/crude human biological materials outside Nepal is strictly prohibited . Only extracted and amplified samples may be transported abroad, subject to:
- CV of sample handlers submitted to NHRC
- Commitment letter from foreign laboratory
- Destruction commitment upon analysis completion
Regulatory Requirements for DDA Licensing
Drug Categories Requiring Clinical Trial Approval Nepal
| Category | Requirement | Data Needed |
|---|---|---|
| New Chemical Entities (NCEs) | Full clinical trial license | Phase I, II, III data; preclinical toxicology |
| Generic drugs | Bioequivalence study approval | In vitro dissolution or in vivo bioequivalence |
| Biological products | Specialized evaluation | Characterization, immunogenicity, stability |
| Herbal/Ayurvedic medicines | Modified requirements | Botanical identification, traditional use documentation, safety data |
| Vaccines | Enhanced scrutiny | Preclinical immunogenicity, Phase I-III safety/efficacy |
Good Clinical Practice (GCP) Compliance
All trials must follow ICH-GCP E6(R2) guidelines :
- Qualified investigators and study staff
- Adequate facilities and resources
- Proper investigational product management
- Accurate data recording and verification
- Independent ethics committee oversight
- Participant rights protection
DDA Inspection and Enforcement
Post-Approval Monitoring
Since 2023, DDA has significantly strengthened clinical trial oversight :
| Activity | Frequency | Purpose |
|---|---|---|
| Site inspections | At least once during trial | GCP compliance verification |
| Adverse event review | Ongoing | Participant safety monitoring |
| Data integrity audits | Periodic | Source document verification |
| Final report review | Upon completion | Outcome assessment |
First-Ever DDA Site Inspection
In June 2023, DDA conducted its first regulatory audit of a clinical trial site in Kathmandu using newly developed inspection checklists and trained personnel . This milestone marked a significant advancement in Nepal's clinical trial regulatory maturity.
Penalties for Non-Compliance
| Violation | Penalty | Legal Basis |
|---|---|---|
| Conducting trial without DDA license | Up to 3 years imprisonment; NPR 25,000 fine | Drug Act Section 34 |
| Adulteration or misrepresentation of trial data | Up to 3 years imprisonment; NPR 25,000 fine | Drug Act Section 29 |
| Violation of ethical standards | NHRC suspension; funding termination; publication ban | NHRC guidelines |
| Failure to report SAEs | License suspension; protocol termination | DDA regulations |
Recent Reforms and Digital Transformation (2024–2026)
WHO-NHRC Online Ethical Review System
In December 2024, WHO and NHRC signed an MoU to establish a national online ethical review system :
| Feature | Benefit |
|---|---|
| Harmonized ERB-IRC portal | Streamlined submission across all review committees |
| Standardized review standards | Alignment with international ethical norms |
| Efficient data management | Secure, transparent processing of review data |
| Clinical trial registry integration | WHO-compliant trial registration |
Capacity Building Initiatives
| Initiative | Partner | Impact |
|---|---|---|
| Clinical trial inspection training | MTaPS/WHO | DDA staff trained in GCP and site audit |
| Research ethics workshops | NHRC | Clinician awareness of trial vs. observational study distinction |
| ICMR collaboration | India | Cross-border health research, regulatory harmonization |
| IVI partnership | International Vaccine Institute | Vaccinology research capacity building |
Challenges in Clinical Trial Approval Nepal
Despite progress, significant challenges persist :
| Challenge | Impact | Mitigation Strategy |
|---|---|---|
| Limited qualified manpower | Documentation errors; GCP non-compliance | Training programs; international partnerships |
| Incomplete legal framework | Regulatory gaps; enforcement difficulties | Draft regulations pending approval |
| Lack of central laboratories | Bio-sample analysis delays | Category A lab expansion; local analysis preference |
| IRC capacity limitations | Delayed ethical reviews | NHRC training; online system implementation |
| Funding constraints | Limited investigator-initiated trials | Government liaison; international sponsor engagement |
| Post-trial data archiving | 5–25 year storage requirements | Dedicated research document storage facilities |
FAQs on Clinical Trial Approval Nepal
1. Who approves clinical trials in Nepal?
Two authorities: NHRC provides ethical clearance; DDA issues clinical trial license .
2. How long does clinical trial approval take in Nepal?
NHRC ethical clearance: 4–8 weeks. DDA license: 2–4 weeks after NHRC approval. Total: 6–12 weeks .
3. What documents are required for NHRC ethical approval?
Protocol, informed consent forms, investigator CV, budget, insurance, risk assessment, and data safety plan .
4. Is clinical trial data required for all drug registrations?
Only for New Chemical Entities and products not previously approved elsewhere. Generic drugs may use bioequivalence data .
5. Can foreign researchers conduct clinical trials in Nepal?
Yes, but at least one co-investigator must be a Nepali citizen .
6. What is the cost of clinical trial approval?
NHRC charges 3% of total research budget for projects over $10,000; $100 for projects under $10,000 . DDA fees vary by drug category.
7. Are biological samples allowed outside Nepal?
Raw/crude samples: No. Only extracted/amplified samples with NHRC approval and laboratory commitment letters .
8. What is GCP and is it mandatory?
Good Clinical Practice—international ethical and scientific quality standard. Mandatory for all DDA-licensed trials .
9. How are adverse events reported?
Serious adverse events must be reported within 24 hours to both NHRC and DDA .
10. Is there a national clinical trial registry?
Yes—the Nepal Clinical Trials Registry (NCTR) operated by NHRC .
11. What happens if I modify the protocol after approval?
Submit an amendment request to NHRC before implementing changes .
12. Can Ayurvedic medicines undergo clinical trials?
Yes, with modified requirements. Must be conducted in government-approved Ayurvedic hospitals with inpatient and laboratory facilities .
13. What is the penalty for conducting trials without approval?
Up to 3 years imprisonment and NPR 25,000 fine under Drug Act Section 34 .
14. Does Nepal have dedicated clinical trial units?
Not yet. Establishment of a national clinical research unit is a recognized priority .
15. How has COVID-19 affected clinical trials in Nepal?
Accelerated regulatory development; increased trial awareness; Nepal recruited second-highest participants globally in the RECOVERY trial .
Attorney Nepal PVT LTD: Your Clinical Trial Regulatory Partner
Attorney Nepal PVT LTD provides comprehensive legal and regulatory services for clinical trial approval Nepal. Our specialized team offers:
- Regulatory strategy development for NHRC and DDA navigation
- Protocol compliance review against National Ethical Guidelines
- Informed consent document drafting in Nepali and English
- NHRC ERB application preparation and representation
- DDA clinical trial license application and follow-up
- Contract negotiation with sponsors, CROs, and institutions
- Adverse event reporting compliance and liability management
- Biological sample transfer authorization assistance
- Post-approval monitoring support and inspection readiness
- International partnership agreements and MoU drafting
With deep expertise in Nepal's pharmaceutical regulatory framework, Drug Act 2035, NHRC guidelines, and international GCP standards, Attorney Nepal PVT LTD ensures your clinical trials meet all ethical and regulatory requirements. Contact us today for professional clinical trial approval assistance.
References
- Nepal Clinical Trials Registry - NHRC
- NHRC Ethics Review Process - NHRC Official
- WHO and NHRC Sign MoU for Online Ethical Review System - WHO Nepal
- Revisiting Clinical Trial History and Regulatory Mechanisms Nepal - PMC
- Strengthening Clinical Trial with Inspection Readiness - MTaPS
- Clinical Trial Registration Process Nepal - Public Health Update
- Practical Challenges for Clinical Trials Nepal - PMC
- National Guidelines on Clinical Trials - NHRC PDF
- Nepal Drug Approval Process 2026 - Corporate NP
- Clinical Trial Regulations Nepal - Scribd
- Medicine Registration Guidance 2073 - Nepal In Data
- NHRC Ethics FAQ
- Understanding Health Research Ethics Nepal - PMC
Disclaimer
This article is prepared for informational purposes only and does not constitute legal or regulatory advice. Clinical trial approval Nepal requirements, timelines, and fees are subject to change based on NHRC and DDA policies. The online ethical review system is being implemented and may alter current procedures. For project-specific regulatory guidance, consult a qualified pharmaceutical regulatory lawyer or contact NHRC and DDA directly. The information presented is based on the Drug Act 2035, NHRC Act 1991, National Ethical Guidelines, and current regulatory practices as of May 2026. Attorney Nepal PVT LTD shall not be liable for any consequences arising from actions taken based on this content.
This article is for general informational purposes only and does not constitute legal advice. For advice on your specific situation, please contact Attorney Nepal directly.
